You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
益豐藥房(603939.SH):子公司擬投建益豐大藥房第二總部項目 預計總投資3億元
格隆匯 01-07 16:09

格隆匯 1 月 7日丨益豐藥房(603939.SH)公佈,近日,公司全資子公司湖南益豐醫藥有限公司(“益豐醫藥”)與長沙高新技術產業開發區管理委員會簽訂了《項目投資建設合同》,公司擬通過益豐醫藥向長沙高新技術產業開發區管理委員會(“高新區管委會”)申請項目建設用地,並基於用地需求與高新區管委會簽訂項目投資合同。

項目名稱:益豐大藥房第二總部項目,項目擬投資3億元,建設益豐大藥房全國第二總部,建成後主要承載恆修堂二期中藥研發、檢驗、銷售基地;醫藥電商研發、運營及結算中心;益豐大藥房運營管理、採購、銷售及結算中心。該項目用地位於長沙高新區桐梓坡路與興園路交匯處東北角,淨用地面積約59.9畝,土地用途為工業用地,土地使用權年限為50年。上述項目實際用地面積及位置以掛牌出讓時公示面積及位置為準。

長沙高新區作為長株潭“兩型”社會綜合配套改革試驗區、長株潭國家自主創新示範區和湖南湘江新區的核心園區,具有良好的投資環境。本項目投資符合公司長期發展的戰略規劃,有利於促進公司的可持續發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account